Related Experiment Video
Updated: Sep 21, 2025
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in
Yuanyuan Ding1, Zufa Wei1, Jian Li1
1Hubei Province Huangshi Puren Hospital Cardiovascular Medicine, 435002, China.
Insights
Metoprolol succinate combined with Entresto significantly improved cardiac function and coagulation in congestive heart failure patients. This combination therapy enhanced ventricular remodeling and demonstrated good safety for treating CHF.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Congestive heart failure (CHF) remains a significant clinical challenge, necessitating novel therapeutic strategies.
- Optimizing cardiac function and coagulation profiles is crucial for managing CHF patients.
Purpose of the Study:
- To evaluate the combined effects of metoprolol succinate and Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac and coagulation functions in patients with CHF.
Main Methods:
- A study involving 120 CHF patients randomized into a control group (metoprolol succinate) and a study group (metoprolol succinate + Entresto).
- Comparison of clinical efficacy, cardiac function, vascular endothelial function, oxidative stress, and coagulation parameters before and after treatment.
Main Results:
- The study group showed a higher effective rate (98.33% vs. 90.00%) and improved cardiac function (increased LVEF, decreased LVESD/LVEDD).
- Significant improvements were observed in vascular endothelial function, reduced oxidative stress (lower MDA, higher GSH-Px/SOD), and better coagulation indexes (decreased APTT, PT, FIB) in the study group.
- No significant differences in baseline demographics were noted between groups.
Conclusions:
- Entresto combined with metoprolol succinate effectively improves cardiac function, vascular endothelial function, and coagulation in CHF patients.
- This combination therapy demonstrates potential in improving ventricular remodeling with a favorable safety profile.
Objective:
To investigate the effects of metoprolol succinate combined with Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac function and coagulation function in patients with congestive heart failure (CHF).
Methods:
About 120 patients with CHF treated from April 2018 to April 2021 were enrolled in our hospital. The patients were arbitrarily assigned into control group and study group. The control group was cured with metoprolol succinate sustained-release tablets, and the study group was cured with metoprolol succinate sustained-release tablets combined with Entresto. The curative effect, cardiac function, vascular endothelial function, oxidative stress, and coagulation function were compared.
Results:
First of all, we compared the general data, and there exhibited no difference in age, sex, course of disease, hypertension, coronary heart disease, diabetes, atrial fibrillation, and other general data (P > 0.05). Second, we compared the clinical efficacy. The effective rate of the study group (98.33%) was higher (90.00%) (P < 0.05). There exhibited no significant difference in cardiac function indexes before treatment, but after treatment, LVEF increased, LVESD and LVEDD decreased, LVESD and LVEDD in the study group were lower, and LVEF in the study group was higher (P < 0.05). Before treatment, there exhibited no significant difference in vascular endothelial function. However, the levels of CGRP and ET increased and the level of NO decreased, and the level of NO in the study group was lower, while the levels of CGRP and ET in the study group were higher after treatment (P < 0.05). There exhibited no significant difference in oxidative stress indexes before treatment, however, the levels of GSH-Px and SOD increased and the levels of MDA decreased after treatment, while the level of MDA in the study group was lower, while the levels of GSH-Px and SOD in the study group were higher (P < 0.05). Finally, we compared the indexes of blood coagulation function. There exhibited no significant difference before treatment, but after treatment, the levels of APTT, PT, and FIB decreased, and the levels of APTT, PT, and FIB in the study group were lower (P < 0.05).
Conclusion:
Clinical practice demonstrated that LVESD and LVEDD decreased and LVEF increased after treatment with Entresto combined with metoprolol in CHF patients, which can effectively facilitate cardiac function and vascular endothelial function, reduce oxidative stress reaction, and improve blood coagulation indexes, suggesting that Entresto combined with metoprolol can improve ventricular remodeling with good safety.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure Drugs: Inotropic Agents
01:29Heart Failure II: Pathophysiology
01:22Heart Failure VI: Adjunct Therapies